公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry | Drilon A.; Duruisseaux M.; Han J.-Y.; Ito M.; Falcon C.; Yang S.-R.; Murciano-Goroff Y.R.; Chen H.; Okada M.; Molina M.A.; Wislez M.; Brun P.; Dupont C.; Branden E.; Rossi G.; Schrock A.; Ali S.; Gounant V.; Magne F.; Blum T.G.; Schram A.M.; Monnet I.; JIN-YUAN SHIH ; Sabari J.; Pérol M.; Zhu V.W.; Nagasaka M.; Doebele R.; Camidge D.R.; Arcila M.; Ou S.-H.I.; Moro-Sibilot D.; Rosell R.; Muscarella L.A.; Liu S.V.; Cadranel J. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 30 | 20 | |
2005 | The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice | Okada M.; Takemoto Y.; Okuno Y.; Hashimoto S.; Yoshida S.; Fukunaga Y.; Tanaka T.; Kita Y.; Kuwayama S.; Muraki Y.; Kanamaru N.; Takai H.; Okada C.; Sakaguchi Y.; Furukawa I.; Yamada K.; Matsumoto M.; Kase T.; Demello D.E.; Peiris J.S.M.; PEI-JER CHEN ; Yamamoto N.; Yoshinaka Y.; Nomura T.; Ishida I.; Morikawa S.; Tashiro M.; Sakatani M. | Vaccine | 49 | 42 | |
2007 | Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models | Okada M.; Okuno Y.; Hashimoto S.; Kita Y.; Kanamaru N.; Nishida Y.; Tsunai Y.; Inoue R.; Nakatani H.; Fukamizu R.; Namie Y.; Yamada J.; Takao K.; Asai R.; Asaki R.; Kase T.; Takemoto Y.; Yoshida S.; Peiris J.S.M.; PEI-JER CHEN ; Yamamoto N.; Nomura T.; Ishida I.; Morikawa S.; Tashiro M.; Sakatani M. | Vaccine | 31 | 25 | |
2006 | Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models | Okada M.; Takemoto Y.; Okuno Y.; Hashimoto S.; Fukunaga Y.; Tanaka T.; Kita Y.; Kuwayama S.; Muraki Y.; Kanamaru N.; Takai H.; Okada C.; Sakaguchi Y.; Furukawa I.; Yamada K.; Izumiya M.; Yoshida S.; Matsumoto M.; Kase T.; Peiris J.S.M.; DeMello D.E.; PEI-JER CHEN ; Yamamoto N.; Yoshinaka Y.; Nomura T.; Ishida I.; Morikawa S.; Tashiro M.; Sakatani M. | Advances in Experimental Medicine and Biology | 1 | 2 | |
2017 | Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial | Nash P.; Kirkham B.; Okada M.; Rahman P.; Combe B.; Burmester G.-R.; Adams D.H.; Kerr L.; Lee C.; Shuler C.L.; Genovese M.; Ahmed K.; Alper J.; Barkham N.; Bennett R.E.; Garc?a F.J.B.; Alonso R.B.; Blumstein H.B.; Brooks M.S.; Burmester G.-R.; Cagnoli P.; Caldron P.H.; Cantagrel A.; Chen D.-Y.; Churchill M.A.; Jr, Codding C.E.; Combe B.; Deane P.M.G.; Del Giudice J.; Deodhar A.A.; Dhar R.K.; Dokoupilova E.; Egan R.M.; Everding A.; Gal?ndez E.; Genovese M.; Goddard D.H.; Gottlieb A.; Goupille P.; Griffin R.M.; Gupta R.C.; Hall S.; Hatti K.; Howell M.P.; Huang Y.-H.; Jajoo R.; Janssen N.M.; Kiltz U.; Kivitz A.J.; Klein S.J.; Korkosz M.P.; Kotha R.; Kremer J.M.; Lue C.; de la Fuente J.L.M.; Marzo-Ortega H.; Masmitja J.G.; Mease P.J.; Meroni P.L.; Mueller E.C.; Nandagudi A.C.; Nash P.; Fern?ndez-Nebro A.; Neuwelt C.M.; Orbai A.M.; Oza M.R.; Parks D.L.; Pattanaik D.; Rell-Bakalarska M.E.; Rosmarin D.; Roussou E.; Rychlewska-Hanczewksa A.I.; Sikes D.H.; Stack M.T.; Sunkureddi P.; Tahir H.; Tha?i D.; TSEN-FANG TSAI ; Turkiewicz A.M.; Unger L.; Cabello R.V.; Wagner U.; Wei C.-C.; Wells A.F.; Youssef P.; Zielinska A. | The Lancet | 314 | 294 | |
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 722 | 630 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 |